Peptide radiopharmaceuticals in nuclear medicine

European Journal of Nuclear Medicine

Volumn 26, Issue 11, 1999, Pages 1511-1519

  Blok, D ^a   Feitsma, R I J ^b   Vermeij, P ^a   Pauwels, E J K ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Peptides; Radiolabelling; Receptor imaging

Indexed keywords

AMINO ACID; PENTETREOTIDE; PEPTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN 14;

HUMAN; ISOTOPE LABELING; MEDICAL RESEARCH; NUCLEAR MEDICINE; REVIEW;

ANIMALS; HUMANS; ISOTOPE LABELING; PEPTIDES; RADIOPHARMACEUTICALS;

EID: 0032750819     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050488     Document Type: Review

References (85)

1. Serafini AN. From monoclonal antibodies to peptides and molecular recognition units: an overview. J Nucl Med 1993;34: 533-536.
2. Fischman AJ, Babich JW. Radiolabeled peptides: a new class of imaging agents. In: Freeman LM, ed. Nuclear medicine annual 1997. Philadelphia: Lippincott-Raven; 1997: 103-131.
3. Khaw BA. Magic bullets. From muskets to smart bombs. J Nucl Med 1993;34: 2264-2268.
4. Fischman AJ, Babich JW, Strauss HW. A ticket to ride: peptide radiopharmaceuticals. J Nucl Med 1993; 34: 2253-2263.
5. de Bie SH, Ferreira TC, Pauwels EK, Cleton FJ. Immunoscintigraphy for cancer detection: "a thousand ills require a thousand cures". J Cancer Res Clin Oncol 1992; 118: 1-15.
6. Hnatowich DJ. Antibody radiolabeling, problems and promises. Int J Rad Appl Instrum [B] 1990; 17: 49-55.
7. Thakur ML. Radiolabelled peptides: now and the future. Nucl Med Commun 1995; 16: 724-732.
8. Miller L. Synthetic peptides come of age. J Nucl Med 1993; 34: SNM Newsline.
9. Liu S, Edwards DS, Barrett JA. Tc 99m labeling of highly potent small peptides. Bioconj Chem 1997; 8: 621-636.
10. MCAfee JG, Neumann RD. Radiolabeled peptides and other ligands for receptors overexpressed in tumor cells for imaging neoplasms. Nucl Med Biol 1996; 23: 673-676.
11. Reubi JC, Waser B, Schaer JC, et al. Unsulfated DTPA-and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med 1998; 25: 481-490.
12. Spradau TW, Edwards WB, Anderson CJ, Welch MJ, Katzenellenbogen JA. Synthesis and biological evaluation of Tc-99m-cyclopentadienyltricarbonyltechnetium-labeled octreotide. Nucl Med Biol 1999; 26: 1-7.
13. Reubi JC. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med 1997; 41: 63-70.
14. Krenning EP, Bakker WH, Breeman WA, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; I: 242-244.
15. 99mTc. Q J Nucl Med 1996; 40: 221-233.
16. Lister-James J, Moyer BR, Dean RT. Pharmacokinetic considerations in the development of peptide-based imaging agents. Q J Nucl Med 1997; 41: 111-118.
17. 125I. Effect of labeling on distribution and excretion of radioactivity in rats. J Pharm Sci 1999; 88: 577-585.
18. Kennedy JW, Dluhy RG. The biology and clinical relevance of somatostatin receptor scintigraphy in adrenal tumor management. Yale J Biol Med 1997; 70: 565-575.
19. Moody TW, Perry DC. Peptide receptors. In: Williams M, Glennon RA, Timmermans PBMWM, eds. Receptor pharmacology and function. New York: Dekker; 1989: 527-570.
20. Mather SJ, Chianelli M. Radiolabelled cytokines. Q J Nucl Med 1996; 40: 290-300.
21. Breeman WAP, Vanhagen MP, Visserwisselaar HA, et al. In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium 111 DTPA Arg(1)]substance P. J Nucl Med 1996; 37: 108-117.
22. Breeman WA, Kwekkeboom DJ, Kooij PP, et al. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med 1995; 36: 623-627.
23. Powell MF, Grey H, Gaeta F, Sette A, Colon S. Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J Pharm Sci 1992; 81: 731-735.
24. Cuttitta F. Peptide amidation: signature of bioactivity. Anat Rec 1993; 236: 87-93.
25. Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994; 331: 1116-1121.
26. Nibbering PH, Welling MM, den BPJv, Wijngaarden KEv, Pauwels EKJ, Calame W. Radiolabelled antimicrobial peptides for imaging of infections: a review. Nucl Med Commun 1998; 19: 1117-1121.
27. Knight LC, Radcliffe R, Maurer AH, Rodwell JD, Alvarez VL. Thrombus imaging with technetium-99m synthetic peptides based upon the binding domain of a monoclonal antibody to activated platelets. J Nucl Med 1994; 35: 282-288.
28. Lister-James J, Vallabhajosula S, Moyer BR, et al. Pre-clinical evaluation of technetium-99m platelet receptor-binding peptide. J Nucl Med 1997; 38: 105-111.
29. Wolf H, Marschall F, Scheffold N, Clausen M, Schramm M, Henze E. Iodine-123 labelling of atrial natriuretic peptide and its analogues: initial results. Eur J Nucl Med 1993; 20: 297-301.
30. Vanhagen PM, Breeman WAP, Reubi JC, et al. Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med 1996; 23: 1508-1513.
31. Chianelli M, Mather SJ, Martincomin J, Signore A. Radiopharmaceuticals for the study of inflammatory processes: a review. Nucl Med Commun 1997; 18: 437-455.
32. Lewin MJ. Somatostatin receptors. Scand J Gastroenterol Suppl 1986; 119: 42-46.
33. Lamberts WJ, van der Lely A, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334: 246-254.
34. Pless J, Bauer W, Briner U, et al. Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin. Scand J Gastroenterol Suppl 1986; 119: 54-64.
35. Burbach JP, Meijer OC. The structure of neuropeptide receptors. Eur J Pharmacol 1992; 227: 1-18.
36. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 1995; 36: 1825-1835.
37. Hoyer D, Bell GI, Berelowitz M, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995; 16: 86-88.
38. Reubi JC, Schaer JC, Markwalder R, Waser B, Horisberger U, Laissue J. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biol Med 1997; 70: 471-479.
39. Reichlin S. Clinical application of somatostatin receptor imaging [editorial; comment], J Clin Endocrinol Metab 1990; 71: 564-565.
40. 4-(D)Phe]-octreotide, a new octreotide derivative with high affinity for somatostatin receptors. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium and rhenium in chemistry and nuclear medicine 4. Padua: S.G. Editorial; 1995: 395-400.
41. Vallabhajosula S, Moyer BR, Lister James J, et al. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides, J Nucl Med 1996; 37: 1016-1022.
42. Amartey JK. Technetium-99m labeled somatostatin and analogs: synthesis, characterization and in vivo evaluation. Nucl Med Biol 1993; 20: 539-543.
43. Pearson DA, Lister-James J, MCBride WJ, et al. Somatostatin receptor-binding peptides labeled with technetium-99m: chemistry and initial biological studies. J Med Chem 1996; 39: 1361-1371.
44. Tran TA, Mattern RH, Afargan M, et al. Design, synthesis, and biological activities of potent and selective somatostatin analogues incorporating novel peptoid residues, J Med Chem 1997; 41: 2679-2685.
45. Gilon C, Huenges M, Mathä B, et al. A backbone-cyclic, receptor 5-selective somatostatin analogue: synthesis, bioactivity, and nuclear magnetic resonance conformational analysis. J Med. Chem 1998; 41: 919-929.
46. Chakder S, Rattan S. the entire vasoactive intestinal polypeptide molecule is required for the activation of the vasoactive intestinal polypeptide receptor: functional and binding studies on opossum internal anal sphincter smooth muscle. J Pharm Exp Therapeut 1993; 266: 392-399.
47. 99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. J Nucl Med 1999; 40: 352-360.
48. Babich JW, Solomon H, Pike MC, et al. Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection. J Nucl Med 1993; 34: 1964-1974.
49. Abrams MJ, Juweid M, tenKate CI, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 1990; 31: 2022-2028.
50. Fischman AJ, Pike MC, Kroon D, et al. Imaging focal sites of bacterial infection in rats with indium-111-labeled chemotactic peptide analogs. J Nucl Med 1991; 32: 483-491.
51. Sivolapenko GB, Skarlos D, Pectasides D, et al. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur J Nucl Med 1998; 25: 1383-1389.
52. 99mTc-labeled radiopharmaceuticals. Semin Nucl Med 1990; 20: 5-27.
53. Schwochau A. Some fundamental aspects of technetium chemistry. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium in chemistry and nuclear medicine 2. Verona: Cortina International; 1986: 13-23.
54. Davison A. The coordination chemistry of technetium. In: Deutsch E, Nicolini M, Wagner HN, eds. Technetium in chemistry and nuclear medicine. Verona: Cortina International; 1983: 3-14.
55. Davison A, Orvig C, Trop HS, Sohn M, DePamphilis BV. Preparation of oxobis(dithiolato) complexes of technetium(V) and rhenium(V). Inorg Chem 1980; 19: 1988-1992.
56. 99mTc radiopharmaceuticals. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium and rhenium in chemistry and nuclear medicine 3. Verona: Cortina International; 1989: 39-50.
57. 99mTc-labeling of antibodies. Nuklearmedizin 1987; 26: 7-12.
58. 99mTc. Int J Rad Appl Instrum [B] 1991; 18: 667-76.
59. Rhodes BA, Zamora PO, Newell KD, Valdez EF. Technetium-99m labeling of murine monoclonal antibody fragments. J Nucl Med 1986; 27: 685-693.
60. 99mTc labeling of monoclonal antibodies: radiolabeling and in vitro stability. Int J Rad Appl Instrum [B] 1991; 18: 695-703.
61. Welling MM, Hiemstra PS, van den Barselaar MT, et al. Anti-bacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leucocyte accumulation. J Clin Invest 1998; 102: 1583-1590.
62. Thakur ML. Tc-99m labeled sandostatin: preparation and preliminary evaluation. J Labeled Cmpd Radiopharm 1993; 32: 365-367.
63. 99mTc. Int J Appl Radiat. Isot 1984; 35: 617-621.
64. Childs RL, Hnatowich DJ. Optimum conditions for labeling of DTPA-coupled antibodies with technetium-99m, J Nucl Med 1985; 26: 293-299.
65. 2cCore. Inorg Chem 1981; 20: 1629-1632.
66. Fritzberg AR, Abrams PG, Beaumier PL, et al. Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent. Proc Natl Acad Sci USA 1988; 85: 4025-4029.
67. 3S triamidethiols as bifunctional chelating agents for labelling small peptides with technetium-99m. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium and rhenium in chemistry and nuclear medicine 4. Padua: S.G. Editorial; 1995: 383-393.
68. Visser GW, Gerretsen M, Herscheid JD, Snow GB, van Dongen G. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med 1993; 34: 1953-1963.
69. Lei K, Rusckowski M, Chang F, Qu T, Mardirossian G, Hnatowich DJ. Technetium-99m antibodies labeled with MAG3 and SHNH: an in vitro and animal in vivo comparison. Nucl Med Biol 1996; 23: 917-922.
70. Arano Y, Yokoyama A, Furukawa T, et al. Technetium-99m-labeled monoclonal antibody with preserved immunoreactivity and high in vivo stability. J Nucl Med 1987; 28: 1027-1033.
71. Santimaria M, Mains T, Mazzi U, Nicolini M. Trans-Oxochloro [3-diphenylphosphinopropionylglycinato-L-(S-benzyl) cysteinato methyl ester-P,N,N,S] rhenium(V): synthesis, characterization and HPLC analysis. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium and rhenium in chemistry and nuclear medicine 4. Padua: S.G. Editorial; 1995: 149-153.
72. 99mTc-complex. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium and rhenium in chemistry and nuclear medicine 4. Padua: S.G. Editorial; 1995: 343-347.
73. Santimaria M, Blok D, Feitsma RIJ, Mazzi U, Pauwels EKJ. Experiments on a new phosphine-peptide chelator for labelling of peptides with Tc-99m. Nucl Med Biol 1999; 26: 251-258.
74. Bormans G, Cleynhens B, Perdieus D, de Roo M, Verbruggen A. Comparison of benzyl, benzoyl and benzamidomethyl as protective groups for mercaptoacetyltriglycine (MAG3). J Label Comp Radiopharm 1989; 26: 50-52.
75. Kasina S, Rao TN, Srinivasan A, et al. Development and biologic evaluation of a kit for preformed chelate technetium-99m radiolabeling of an antibody Fab fragment using a diamide dimercaptide chelating agent. J Nucl Med 1991; 32: 1445-1451.
76. Bryson N, Lister-James J, Jones AG, Davis AG, Davison A. Protecting groups in the preparation of thiolate complexes of technetium. Inorg Chem 1990; 29: 2948-2951.
77. 188Re labelling of amines and peptides. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium and rhenium in chemistry and nuclear medicine 4. Padua: S.G. Editorial; 1995: 363-366.
78. Anderson GW, Zimmerman JE, Callahan FM. The use of esters of N-hydroxysuccinimide in peptide synthesis. J Am Chem Soc 1964; 86: 1839-1842.
79. Esteban JM, Schlom J, Gansow OA, et al. New method for the chelation of indium-111 to monoclonal antibodies: biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts. J Nucl Med 1987; 28: 861-870.
80. Ram S, Buchsbaum DJ. Synthesis of a new class of isothiocyanatopeptide bifunctional chelating agents for coupling to monoclonal antibodies. Int J Peptide Protein Res 1996; 48: 79-86.
81. Mather SJ, Ellison D, Bard DS. Technetium-99m labelled hybrid receptor-binding peptides. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium and rhenium in chemistry and nuclear medicine 4. Padua: S.G. Editorial; 1995: 491-497.
82. Virgolini I, Kurtaran A, Raderer M, et al. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 1995; 36: 1732-1739.
83. Lambert R, Willenbrock R, Tremblay J, et al. Receptor imaging with atrial natriuretic peptide. Part 1: High specific activity iodine-123-atrial natriuretic peptide. J Nucl Med 1994; 35: 628-637.
84. Blower PJ, Puncher MRB, Kettle AG, et al. Iodine-123 salmon calcitonin, an imaging agent for calcitonin receptors: synthesis, biodistribution, metabolism and dosimetry in humans. Eur J Nucl Med 1998; 25: 101-108.
85. Fischman AJ, Babich JW, Rubin RH. Infection imaging with technetium-99m-labeled chemotactic peptide analogs. Semin Nucl Med 1994; 24: 154-168.